For the year ending 2025-12-31, ORIC had -$13,737K decrease in cash & cash equivalents over the period. -$111,682K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -129,468 |
| Depreciation | 1,220 |
| Stock-based compensation expense | 25,037 |
| Accretion of discount on investments, net | 2,300 |
| Prepaid expenses and other assets | -1,787 |
| Accounts payable and accrued other liabilities | -7,246 |
| Net cash used in operating activities | -110,970 |
| Acquisitions of property and equipment | 712 |
| Purchases of investments | 399,819 |
| Maturities of investments | 252,500 |
| Net cash (used in) provided by investing activities | -148,031 |
| Proceeds from issuance of common stock and pre-funded warrants | 244,369 |
| Issuance costs associated with financings | 2,397 |
| Proceeds from issuance of common stock under espp | 1,313 |
| Proceeds from stock option exercises | 1,979 |
| Net cash provided by financing activities | 245,264 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -13,737 |
| Cash, cash equivalents and restricted cash at beginning of period | 59,897 |
| Cash, cash equivalents and restricted cash at end of period | 46,160 |
Oric Pharmaceuticals, Inc. (ORIC)
Oric Pharmaceuticals, Inc. (ORIC)